Endometrial Cancer News and Research RSS Feed - Endometrial Cancer News and Research

Adherence to cancer prevention guidelines on diet and physical activity may reduce disease incidence

Adherence to cancer prevention guidelines on diet and physical activity may reduce disease incidence

"Behaviors such as poor diet choices, physical inactivity, excess alcohol consumption and unhealthy body weight could account for more than 20 percent of cancer cases, and could, therefore, be prevented with lifestyle modifications," Kohler said, adding that when tobacco exposure is considered, these modifiable issues are believed to be factors in two-thirds of U.S. cancer deaths. [More]
Fetal BPA exposure leads to harmful change in adult uterine response to estrogens

Fetal BPA exposure leads to harmful change in adult uterine response to estrogens

Low levels of BPA exposure may be considered safe, but new research published online in The FASEB Journal, suggests otherwise. In the report, researchers from Yale show that the genome is permanently altered in the uterus of mice that had been exposed to BPA during their fetal development. [More]
Multi-center study may help reassure breast cancer patients taking tamoxifen drug

Multi-center study may help reassure breast cancer patients taking tamoxifen drug

A study led by Loyola Medicine researchers may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer. [More]
New research reveals advances that could change gynecologic cancer standard-of-care treatments

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology. [More]
USP14 enzyme could be promising biomarker for detecting risk of endometrial cancer recurrences

USP14 enzyme could be promising biomarker for detecting risk of endometrial cancer recurrences

Endometrial cancer is the most common gynecologic cancer in the U.S. Most cases are diagnosed at early stage and have good prognosis. Unfortunately, some patients with early stage and low grade endometrial cancer experience recurrence - and the reasons are not entirely clear. [More]
Researchers detect five new genes that increase endometrial cancer risk in women

Researchers detect five new genes that increase endometrial cancer risk in women

An international collaboration of researchers has identified five new gene regions that increase a woman's risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine. [More]
Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals. [More]
ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

Advances in Radiation Oncology, ASTRO's new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy. [More]
Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Researchers have discovered gene-targets (biomarkers) that may enable alternative treatments or the potential design of new drugs that target metastasis-promoting tumor genes. [More]
Johns Hopkins-led study shows disparities in access to minimally invasive hysterectomies for uterine cancer

Johns Hopkins-led study shows disparities in access to minimally invasive hysterectomies for uterine cancer

A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say. [More]
New study shows wide disparities in access to minimally invasive hysterectomies for uterine cancer

New study shows wide disparities in access to minimally invasive hysterectomies for uterine cancer

A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say. [More]
Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression. [More]
Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual. [More]
Survey: One-third of US women use compounded hormones at menopause

Survey: One-third of US women use compounded hormones at menopause

A third of US women who take hormones at menopause are using compounded hormones, shows a new national survey. These women commonly--and mistakenly--think these hormones are safer and offer more benefits than FDA-approved therapies. [More]
PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors. [More]
New AGA guideline recommends colorectal cancer patients to undergo tumor test for Lynch syndrome

New AGA guideline recommends colorectal cancer patients to undergo tumor test for Lynch syndrome

All colorectal cancer patients should undergo tumor testing to see if they carry Lynch syndrome, the most common inherited cause of colorectal cancer, according to a new guideline published in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer. [More]
Aeterna Zentaris reports that DSMB scheduled to close second interim analysis of ZoptEC Phase 3 trial in early October

Aeterna Zentaris reports that DSMB scheduled to close second interim analysis of ZoptEC Phase 3 trial in early October

Aeterna Zentaris Inc. today announced that the independent Data and Safety Monitoring Board for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015. [More]
Meta-analysis confirms oral contraceptives reduce endometrial cancer risk

Meta-analysis confirms oral contraceptives reduce endometrial cancer risk

Oral contraceptive use protects against endometrial cancer, with effects persisting for decades after cessation of use, shows a meta-analysis of individual patient data published in The Lancet Oncology. [More]
Oral contraceptives give long-term protection against endometrial cancer, shows study

Oral contraceptives give long-term protection against endometrial cancer, shows study

Use of oral contraceptives, even for just a few years, gives substantial long-term protection against endometrial cancer, and the longer the pill is used the greater the reduction in risk, according to a detailed re-analysis of all the available evidence, published in The Lancet Oncology journal. [More]
Advertisement